• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Systematic Review Finds Limited Evidence for Dementia Apps

by
November 10, 2026
in Health
Reading Time: 2 mins read
0
Systematic Review Finds Limited Evidence for Dementia Apps

Systematic Review Finds Limited Evidence for Dementia Apps

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A systematic review published in Alzheimer’s Research & Therapy has examined the growing landscape of commercially available digital cognitive-oriented therapies for individuals living with mild cognitive impairment or dementia. The study, led by Francesco Sciancalepore and colleagues, noted that while these applications are increasingly used, evidence regarding their effectiveness and classification remains fragmented.

The research team conducted a comprehensive search across major biomedical databases, including PubMed, Embase, and ISI Web of Science, up to January 7, 2026. The scope of the review was specifically focused on randomized controlled trials and non-randomized studies that assessed commercially available apps.

To provide a structured analysis of the interventions, the authors categorized the apps into three distinct groups: training, stimulation, and rehabilitation. This classification was applied using predefined criteria.

The review included sixty publications that referred to thirty different apps. A significant portion of these studies reported statistically significant improvements in cognitive scores, specifically using the Mini-Mental State Examination and the Montreal Cognitive Assessment. However, the authors emphasized that while these improvements were statistically significant, the effect sizes were generally small to moderate.

Methodological weaknesses emerged as a prominent theme in the findings. The review noted that sample size calculations were often absent. Furthermore, the clinical relevance of the observed improvements was inconsistently addressed across the studies.

The assessment of study quality revealed that most of the randomized controlled trials included in the review showed a high risk of bias. Quality of randomized controlled trials was assessed using the Cochrane Risk of Bias tool.

Another notable gap identified by the authors was the limited attention given to caregiver outcomes.

The authors concluded that while the digital cognitive-oriented therapies are promising, the current evidence is limited by these methodological weaknesses and the lack of a clear, harmonized regulatory framework. The review calls for more rigorous trials with clinically meaningful outcomes.

Subject of Research: Systematic review of commercially available apps for dementia and mild cognitive impairment

Article Title: Commercially available apps for the treatment of people living with dementia and mild cognitive impairment: a systematic review. What evidence and what urgencies from a public health perspective?

Article References: Sciancalepore, F., Ancidoni, A., Paggetti, A., Fabrizi, E., Morelli, S., Lacorte, E., Bacigalupo, I., Gatta, F. D., Simoni, M., Gasparini, M., Zanella, A., Stracciari, A., Marra, C., Caffarra, P., Gabelli, C., & Vanacore, N. (2026). Commercially available apps for the treatment of people living with dementia and mild cognitive impairment: a systematic review. What evidence and what urgencies from a public health perspective?. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-026-02206-1

Image Credits: AI Generated

DOI: 10.1186/s13195-026-02206-1

Keywords: dementia, mild cognitive impairment, digital health, systematic review, cognitive therapy, clinical trials, public health, Alzheimer's, Commercially, available, apps, treatment

News Source: Cassandra Pierce. (November 10, 2026). Systematic Review Finds Limited Evidence for Dementia Apps. Scienmag.

Tags: Alzheimer'sappsAvailableClinical Trialscognitive therapycommerciallydementiaDigital Healthmild cognitive impairmentPublic Healthsystematic reviewtreatment
Share12Tweet7Share2ShareShareShare1

Related Posts

Cardiovascular Disease Significantly Increases Economic and Humanistic Burden in Kidney Failure

Cardiovascular Disease Significantly Increases Economic and Humanistic Burden in Kidney Failure

November 17, 2026
Thai Hypertension Study Reveals Shifts in Cardiovascular Risk Factors, 2011–2018

Thai Hypertension Study Reveals Shifts in Cardiovascular Risk Factors, 2011–2018

November 17, 2026

Delayed Thymopoiesis Follows Thymus Transplantation and Infection in Athymic Infant

November 17, 2026

Anemic Surgical Patients Suffer Greater Microvascular Flow Impairment Under Fluid Therapy

November 17, 2026

POPULAR NEWS

  • Pharmacist Prescribing for Urinary Tract Infections Shows High Symptom Resolution

    Pharmacist Prescribing for Urinary Tract Infections Shows High Symptom Resolution

    29 shares
    Share 12 Tweet 7
  • Bioactive Adrenomedullin Rises During Hemorrhagic Shock and Stabilizes With Fluid Resuscitation

    29 shares
    Share 12 Tweet 7
  • Serious Gaming Platform Validated for Basic Laparoscopic Skills Training

    29 shares
    Share 12 Tweet 7
  • Anti-Aging Drugs Show Sex-Specific Interleukin-11 Effects in Mouse Abdominal Fat

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Optimization Model Compresses Construction Schedules to Sixty-Two Days Under Periodic Budget Caps

Saudi Residential Code Yields Higher Seismic Design Forces Than General Standard

Dendritic Cell Virus-Like Vesicles Repurpose Arc Gene for Cancer Vaccination

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.